cyrilzakka/clinical-trials huggingface dataset:
Non Invasive Brain Evaluation and Treatment for Neuropathic Pain

This trial is designed to preliminary evaluate the efficacy and safety of NIBS system for evaluation and treatment of neuropathic pain. The NIBS system evaluates brain neuronal network activity and customizes a personalized treatment utilizing low current non invasive brain stimulation technology for neuropathic pain with central component. this is single meeting trial which includes brain activity evaluation and a single treatment and sham treatment. The goal of the study is to evaluate the central brain component of neuropathic pain subjects, and the effect of conventional tDCS treatment.

Neuropathic pain is a pain which persists after nerve injury has healed and results from significant functional and structural changes in the nervous system similar to memory processes. As a result, neuropathic pain has been proposed to be "a persistence of the memory of pain and/or the inability to extinguish the memory of pain evoked by an initial inciting injury". A firm conclusion in the neurobiology of learning and memory is that different types of memory have distinct mechanisms (e.g., declarative memory vs procedural memory). A similar distinction can be made in pain: various chronic pain states have distinct central mechanisms . Accumulating evidence suggests that chronic pain is a type of nociceptive memory mediated by structural and functional plasticity in by multiple pathways at cortical, subcortical, spinal, and peripheral levels.Elucidating the basal neuronal signature of the person suffering from chronic pain enables to optimizing a treatment which in all studies was constant for all patients regardless of their basal activity

In this study participants will undergo diagnosis of the personalized central manifestation characteristics of the neuropathic pain and evaluate the efficacy of a standard, most commonly used tDCS treatment, based on the diagnosis.

for this purpose a single meeting will take place during which participants will undergo evaluation, sham treatment and standard tDCS treatment.

Eligibility Criteria:
Inclusion Criteria:

* Neuropathic pain diagnosis by pain physician Up to 3 months before trial onset.
* Current NPRS\>4

Exclusion Criteria:

* Neurological illness causing structural brain damage (e.g. Stroke, TIA)
* Psychiatric disease
* History of loss of consciousness
* Epilepsy or epilepsy in a first degree relative
* Medical implants
* Pregnancy
Bronchioscopic Lung Volume Reduction (BLVR)

For patients with emphysema, lung volume reduction by insertion of endobronchial valves could be an expedient approach to improve the diaphragm function and the strength of breathing muscles. Therefore in the present study investigators intend to examine, whether the lung volume reduction by valves might improve the physical capacity and the quality of life.

In line with routine explorations it is necessary to clarify whether a patient is suitable for the lung volume reduction by insertion of endobronchial valves. To address this question lung function diagnostics, 6-minutes-walk-test, blood withdrawal, CT of the thorax, lung perfusion scintigraphy and transthoracic echocardiography have to be performed.

After confirmation of the suitability for the endoscopic lung volume reduction patients who fulfill all other eligibility criteria will be educated about the aim and performance of the study by an investigator.

Following examination will be performed additional due to the study: determination of the strength of breathing muscles via sniff nasal pressure (PImax, PE max, P0.1), determination of the life quality index via St.-George-questionary and determination of the depression score via the Short Form 8 (SF-8) Health Survey.

After that endobronchial valve will be implanted and a permanent post-operative examination will be performed for 24 hours.

Three, respectively nine month after the implanting follow up exploration will be performed on the study patients. Once again the determination of the strength of breathing muscles, the life quality index via St.-George-questionary and the depression score via SF-8 will be performed to clarify an improvement of the physical capacity and the quality of life

Eligibility Criteria:
Inclusion Criteria:

* bilateral lung emphysema after CT
* previous guidelines-based therapy of COPD (including vaccinations against Pneumococcal infections and seasonal influenza)
* nicotine abstention for not less than three months, documented by CO-HB (haemoglobin) \< 2%
* FEV 1 (Forced Expiratory Volume 1 / one second capacity) ≤ 45% of reference value, after bronchodilatation
* total lung capacity (TLC) ≥ 100% of reference value
* residual volume (RV) ≥ 175% of reference value
* patient's suitability for endoscopic lung volume reduction according to multidisciplinary decision of pneumology and thorax surgery division.
* signed Informed Consent
* understanding of the nature, significance and implications of the study
* ability to understand and follow instructions of the study stuff

Exclusion Criteria:

* echo-cardiographic right ventricular pressure (PAPsys) \> 50 mmHg
* indication for a permanent anticoagulation therapy (besides ASS)
* pulmonal cachexia
* pregnancy and lactating
* permanent treatment with \> 20 mg Prednison per day
* hospitalisation due to a COPD-exacerbation in the last 3 months
* \> 3 steroid-treated exacerbations in the last year
* Increase of FEV1 (Forced Expiratory Volume) ≥ 20% after bronchodilatation
* severe diffusion impairment (DLCO \< 20%)
Efficacy and Safety Study of Vicagrel in Patients With Acute Coronary Syndrome (ACS) Undergoing Percutaneous Coronary Intervention (PCI)

This is a multi-center, randomized, double-blind, double-dummy, parallel-controled, phase III trial, aiming to evaluate the effectiveness and safety of long-term continuous administration of Vicagrel capsules in ACS patients undergoing PCI.


Eligibility Criteria:
Inclusion Criteria:

* Patients between 18 and 80 years old, with no gender restrictions.
* Patients diagnosed with ACS and scheduled for PCI, including STEMI and NSTE-ACS (UA/NSTEMI).
* Voluntarily sign the ICF and be able to follow the visit arrangements specified in the protocol during the trial period.

Exclusion Criteria:

* Expected survival time\<12 months;
* Severe liver dysfunction (non heart disease induced ALT or AST\>3x ULN) and cirrhosis;
* Pregnant or lactating women, or participants and their partners who plan to become pregnant during the trial period;
* The researchers determined that other reasons were not suitable for participants in this experiment.
Creatine Kinase Levels and Clinical and Functional Parameters in Parajiu-jitsu Athletes

Introduction: Evidence indicates that muscle damage caused by exercise can lead to functional, biochemical and clinical damage. Therefore, it is pertinent to perform investigations related to the muscle damage marker, creatine kinase with clinical and functional responses. These outcomes encompass an intrinsic potential for understanding the real magnitude of interpretation of classic signals in athletic environments and monitoring of athletes, contributing to specific actions. Objective: To verify the correlation between clinical signs (pain and perception of recovery), functional (muscular strength) and the behavior of CK levels, in the moments following a simulated fight. METHODS: Six male parajiu-jitsu practitioners (34-44 years) were included in the study. The participants attended the collection site 4 times, with a 24-hour interval between sessions, characterizing the following collection moments: baseline, post-exertion, 24, 48 and 72 hours after the simulated fight. Data on pain (visual analogue scale - EVA), perception of recovery (Likert Scale), muscle strength (Dynamometry) and blood samples for CK analysis were collected. All parameters described were measured at all times of collection. For the analysis of the association between behavior of CK levels, clinical and functional variables, the Odds Ratio test and 95% confidence interval were used. For the gross values, the Pearson test was used according to the normality of the data.

Participants will be intentionally allocated into two groups, G1 consisting of professional athletes and G2 consisting of amateur athletes. This division was carried out to guarantee homogeneous stratification between participants with level of conditioning and similar training. The anonymity of the participants will be guaranteed. There will be masking of the participants, investigator and evaluator of the results that were blind to the hypotheses and allocation in groups, adopted in the study. All participants regularly attended the same training center and no sports injuries that might compromise athletic performance will be reported during the survey.

Eligibility Criteria:
Inclusion Criteria:

* Jiu-Jitsu paratroopers were included. To be included in the study participants should report absence of anemia, inflammation, diabetes, cardiovascular disease, and musculoskeletal injuries in the six months prior to data collection. In addition, participants were instructed to refrain from anti-inflammatory drugs, analgesics, alcoholic beverages, and tobacco and did not perform any extra exercise during the study.

Exclusion Criteria:

* withdrawal of participants for personal reasons
TPC vs PF as Induction Chemotherapy Combined With CCRT for Stage IVa-b Nasopharyngeal Carcinoma

The purpose of this study is to compare the survival and toxicity of TPC (TAXOL, DDP AND CAPECITABINE ) VS PF (cisplatin and 5-Fluorouracil) as induction chemotherapy combined with concurrent chemoradiotherapy (CCRT) for stage IVa-b nasopharyngeal carcinoma patients in endemic area.

This is a prospective, parallel, randomized, open labeled, multicenter phase III clinical trial to compare the survival and toxicity of TPC VS PF as induction chemotherapy combined with CCRT for stage IVa-b nasopharyngeal carcinoma patients in endemic area.The primary endpoint is failure free survival (FFS）.The secondary endpoints are overall survival(OS）,progression-free survival（PFS）, local-regionally relapse free survival(LRFS), distant metastasis free survival（DMFS)and toxicities.

Eligibility Criteria:
Inclusion Criteria:

* WHO II or III pathological type
* stage Ⅳa or Ⅳb (UICC 7th edition)
* no anticancer treatment before
* no malignant history
* both gender, 18-60 years old
* enough liver function: TBIL≤ULN；AST/ALT≤2.5×ULN；ALP≤5×ULN
* enough kidney function: Clcr≥80 mL/min
* enough hemo: ANC≥2×109/L, PLT≥100×109/L and HB≥9g/dL
* no sever heart, lung disfunction
* PS≤2

Exclusion Criteria:

* previous anticancer treatment
* distant metastasis
* pregnant or breasting female
* can not access to followup
* enrolled in other therapeutic clinical trial
* sever infection and internal disease
* sever disfunction of heart, lung, kidney, liver, etc
* TBIL\>ULN；AST/ALT\>2.5×ULN；ALP\>5×ULN
* with factors that will affect the administration, distribution,metabolism or evacuation.
* using immunosuppressive agents after organ transplantation
* other malignant history
Vaccine Prevention of Rabies Adopts 4-shot Immunization Method

A phase III clinical trial to evaluate the immunogenicity and safety of freeze-dried human rabies vaccine (Vero cell) developed by Changchun Zhuoyi Biological Co., Ltd. inoculated in a 4-dose procedure (2-1-1)

It is to prove that the freeze-dried human rabies vaccine (Vero cell) in the population aged 10-60 years, the four dose vaccination program is not inferior to the five dose vaccination program, and the safty、antibody positive conversion rate and geometric mean concentration of the four dose group of the test vaccine are not inferior to the five dose program group 14 days after the first dose vaccination.

To compare the immunogenicity of people aged 10-60 years old who were vaccinated 6 and 12 months after the whole vaccination, so as to evaluate the antibody positive rate and GMT 6 and 12 months after the test vaccine was vaccinated.

Eligibility Criteria:
Inclusion Criteria:

* The age is 10-60 years old;
* Underarm temperature ≤ 37.0 ℃.

Exclusion Criteria:

* Have a history of rabies vaccine immunization or use of rabies virus passive immunization agents；
* Has been diagnosed with congenital or acquired immunodeficiency disease；
* Pregnancy (including positive urine pregnancy test) or lactation, planned pregnancy preparation within 2 months.
QuitAdvisorDDS: A Point-of-Care Tobacco Cessation Tool for Dental Settings

Using a single-arm trial design, this study will examine the feasibility and acceptability of evaluating QuitAdvisorDDS, a clinical decision support software application designed to facilitate implementation of evidence-based tobacco treatment interventions into the dental setting. The study will examine the feasibility and acceptability of evaluating the impact of the QuitAdvisorDDS tool on patient outcomes related to tobacco use and cessation attempts as well as provider knowledge, attitudes, and practices regarding tobacco treatment. Practitioners (dentists and hygienists) will complete surveys at baseline and follow-up, while patients will complete surveys at baseline and 1-month follow-up. An embedded substudy will also evaluate the feasibility and acceptability of collecting biospecimens (saliva) to serve as biochemical verification of smoking status.


Eligibility Criteria:
Inclusion Criteria:

* Receives dental care from a participating practitioner;
* Is age 18 or older;
* Self-reports tobacco use within the past month;
* Willing to comply with all study procedures and be available for the duration of the study;
* Willing to provide verbal informed consent;
* Has access to a telephone, and agrees to receive text messages, emails, or telephone calls related to the study. (The patient's preferred method of contact will be ascertained).
* Willing to be contacted on a regular basis by each of these entities: the practice;Regional Coordinators (RC) and/or University of Kentucky (UK) researchers; and
* Willing to provide contact information of one person living at a different address who will know the patient's whereabouts in the event the patient cannot be reached.

Exclusion Criteria:

* Psychiatric disability or mental illness judged by the practitioner to be clinically significant so as to preclude informed consent or compliance with procedures of study visits.
* Cognitive impairment judged by the practitioner to be significant so as to preclude informed consent or compliance with procedures of study visits.
Swallowable Cannabigerol Tablets for Sleep Quality In Veterans (Veterans Exploring Cannabigerol for Sleep)

New methods for the treatment and support of Veterans experiencing sleep issues is critically needed. LEVEL's unique, targeted effects-based cannabis products provide a unique opportunity to study the therapeutic safety and efficacy of cannabigerol (a non-psychoactive cannabinoid) with a controlled dosage. Study participants will participate in an interventional, placebo-controlled, triple-blind pre-post study design. Participants will have a four-week run-in phase followed by an eight-week treatment phase with a CBG ProtabTM or placebo ProtabTM in a swallowable tablet form. During the study, participants will answer questions assessing their sleep, alcohol and drug use, and quality of life, among others. They will also wear a Fitbit Inspire 2 to collect biometric data.


Eligibility Criteria:
Inclusion Criteria:

* Veteran status
* MOS Sleep Problems Index II \> 30
* California resident
* Participants must own their own smartphone device to use for the study. Devices must meet the following criteria:
* Participants must be comfortable reading study instructions in English and communicating with study team in English
* Be willing to commit to study dosing, completing evaluation instruments, and following study protocol activities.
* If female and of childbearing potential, agree to use an effective form of birth control during study participation.

Exclusion Criteria:

* If using sleep medications, medication and dosage have not been changed in the past month and will remain unchanged for the duration of the study
* If using other psychotropic medications, medication and dosage have not been changed in the past 2 months, and will remain unchanged for the duration of the study
* Prior observation that the prospective participant has stopped breathing or observed choking/gasping during their sleep
* Previous diagnosis of sleep apnea (participant reported) without use of a CPAP (or similar PAP device) for at least the prior 4 weeks
* Currently in a Cognitive Behavioral Therapy for Insomnia (CBTI) program
* Women who are currently pregnant, trying to become pregnant, or breastfeeding
* Currently using CBG on a regular basis
* Participant has already participated in this study
The Role of Serum Anticholinergic Activity in ACVB Patients

Drugs with anticholinergic potential increase the risk of postoperative transient and persistent cognitive dysfunction especially in cardiac patients. The investigators main goal is to identify preoperative risk factors and to monitor postoperative patients' state in relation to SAA activity and bilateral BIS-EEG changes.


Eligibility Criteria:
Inclusion Criteria:

* written compliance to the study participation
* a good knowledge in German speech
* no red/ green blindness
* no previous neurological and/or psychiatric illness
* good ability to see and to hear
* Mini-Mental-State-Examination (MMSE) better than 25 points

Exclusion Criteria:

* no written compliance to the study participation
* bad knowledge in German speech
* red/ green blindness
* previous neurological and/or psychiatric illness
* no ability to see and to hear
* Mini-Mental-State-Examination (MMSE) lower than 25 points
Quantifying the Trainability of Peripheral Nerve Function in Young and Older Adults.

The purpose of this project is to identify the effects of hand grip resistance training on nerve speed of the hand muscles and to quantify whether age plays a role in those effects. Two groups (young and older adults) underwent a 4-week resistance training intervention with nerve conduction velocity measured before and after. There were also two control groups (young and older adults) who performed the testing 4 weeks apart, but did not engage in the intervention.

Studies have shown that nerve speed slows with advancing age. As a result, slower nerves may result in slower movement speed and can alter response time. The investigators propose that a resistance training intervention may elicit positive adaptations to the nerves. The purpose of this project is to identify the effects of hand grip resistance training on nerve speed of the hand muscles and to quantify whether age plays a role in those effects. Two groups (young and older adults) underwent a 4-week, at-home, resistance training intervention with nerve conduction velocity (m/s) measured before and after. There were also two control groups (young and older adults) who performed the testing 4 weeks apart, but did not engage in the intervention. Other outcome measures included nerve size, via ultrasound, maximal handgrip strength, and hand dexterity.

Eligibility Criteria:
Inclusion Criteria:

* Apparently healthy adults 18 - 100 years old.

Exclusion Criteria:

* If you have been notified by a physician to refrain from exercise due to cardiovascular issues.
* Known orthopedic or neuromuscular limitations or illness of the upper extremities.
* Known neuromuscular disorders.
* Individuals that are experiencing a fever (\> 100.4° F) or have identified as symptomatic on the COVID-19 screening questionnaire may not participate at this time.
Randomized Controlled Trial of Standard Versus Systemic Decolonization Therapy for the Eradication of Methicillin-resistant Staphylococcus Aureus (MRSA) Colonization

MRSA decolonization may reduce the risk of subsequent MRSA infection and further transmission. A recent randomized controlled trial demonstrated that systemic decolonization may be safe and effective among hospitalized patients when compared to no treatment. As a large number of the investigators patients require re-admission and further transmission may take place in the community, the investigators are comparing the standard decolonization protocol for MRSA eradication to the systemic decolonization protocol among an ambulatory population.

Standard decolonization protocols, which use only topical agents, are limited in efficacy. The method of systemic decolonization to be studied here appears to have greater efficacy than the standard approach using only topical agents. However, concerns have been raised that the increased use of systemic antibiotics may lead to increased levels of drug resistance adverse effects, without sustained decolonization. This study seeks to provide further data to help answer these questions and provide guidance for further policy development and implementation.


Eligibility Criteria:
Inclusion Criteria:

* Any patient colonized with MRSA

Exclusion Criteria:

* Currently on treatment with antibiotics
* Pregnant or breastfeeding women
* Active infection
* Hepatic cirrhosis or abnormal INR due to liver disease
* Decolonization in the previous two (2) months
* MRSA bacteria resistant to one or more of the study medications
* AST and ALT levels more than five times the upper limit of normal.
Digitalization Playful Module of Motor Function Measure Assessment for Children With Neuromuscular Disorders, MFM-Play Pilot Study.

The Motor Function Measure (MFM) is a functional rating scale consisting of 32 items assessing motor functional abilities in a person with neuromuscular disease.

By exploring the potential of digital technologies applied to MFM, for each item completion we want to create digital animations containing different playful and informative scenarios. This digital evolution aims to standardize assessment on the therapist's side, but also to improve acceptance of scale and patient participation.

Despite the modification of the MFM completion by digital animation, the study hypothesis is that the metrological qualities of the scale are retained.

Through the MFM-Play pilot study, the objective is to test 5 items of the MFM-Play scale before carrying out a validation study of the total MFM-Play.


Eligibility Criteria:
Inclusion Criteria:

* Girls and boys with a neuromuscular disease
* Aged 6 to 11 years old
* With parental assent

Exclusion Criteria:

* Patients participating to a therapeutic trial
* Patients without compartmental capacities to participate normally to the MFM.
Cryoablation Combined With PD-1 Antibody and Bevacizumab for Hepatocellular Carcinoma

To explore the safety and efficacy of cryoablation combined with PD-1 antibody and bevacizumab for patients with hepatocellular carcinoma resistance to PD-1/L1 antibody.


Eligibility Criteria:
Inclusion Criteria:

1. Age between 18 and 80 years old, and expected survival is longer than 3 months
2. Clinically or pathologically diagnosed as primary hepatocellular carcinoma
3. Disease progression assessed according to mRECIST criteria after PD-1/L1 antibody treatment
4. Child-Pugh score of liver function A/B (\< 7)
5. At least one lesion is suitable for mRECIST assessment
6. Strength score (ECOG): 0-1
7. The patient and/or family members agree to join the clinical trial and sign the informed consent form

Exclusion Criteria:

1. Patients whose tumor lesions are not suitable for ablation as assessed by the surgeon
2. Tumor burden greater than ≥70%, or tumor is not suitable for mRECIST standard evaluation
3. Patients with chronic viral hepatitis (hepatitis B, hepatitis C) have a viral load greater than 10\^4 before receiving treatment or do not continue to take antiviral drugs regularly
4. Pregnant patients
5. Combined with other malignant tumors, or have a history of other malignant tumors within 3 years
6. Active autoimmune disease, confirmed immunodeficiency, history of systemic steroid medication
7. Severe renal dysfunction: creatinine (Cr) \> 2 mg/dL or creatinine clearance (CCr) \<30 mL/min, severe heart, lung, brain and other important organ diseases
8. History of gastrointestinal bleeding within 3 months
9. Unable to cooperate with ablation surgery
10. Severe gastroesophageal varices